Biomarkers and novel agents in esophago-gastric cancer: are we making progress?

Area of Science:

• Oncology
• Gastroenterology
• Molecular Biology

Background:

• Esophago-gastric cancer (EGC) presents a significant healthcare challenge, with limited efficacy of conventional chemotherapy in advanced stages.
• The emergence of targeted therapies and immunotherapies represents a paradigm shift in EGC treatment.
• Despite progress, understanding EGC pathogenesis and optimizing novel agent use remain complex.

Purpose of the Study:

• To review the current role and clinical utility of targeted therapies in advanced esophago-gastric cancer (EGC).
• To discuss the biomarkers associated with these novel targeted agents in EGC.
• To provide a comprehensive overview of the current landscape of targeted agents and biomarkers for advanced EGC.

Main Methods:

• Literature review of recent clinical trials and studies on targeted therapies in EGC.
• Analysis of biomarker data related to targeted agent efficacy in EGC.
• Synthesis of current research findings on novel agents and their corresponding biomarkers.

Main Results:

• Novel targeted agents and immunotherapies show clinical utility in advanced EGC.
• Biomarkers are crucial for identifying patient populations likely to benefit from specific targeted therapies.
• Recent trial results underscore the complexity of EGC and the need for further research.

Conclusions:

• Targeted therapies, guided by biomarkers, are increasingly important in managing advanced EGC.
• Continued research is essential to overcome challenges and optimize the use of novel agents in EGC.
• A comprehensive understanding of targeted agents and biomarkers is vital for advancing EGC treatment strategies.